Market Overview

According to fortune business insights, the global clinical trial supplies market size was valued at USD 5.45 billion in 2025. The market is projected to grow from USD 5.83 billion in 2026 to USD 11.80 billion by 2034, exhibiting a CAGR of 9.2% during the forecast period. North America dominated the clinical trial supplies market with a market share of 38.16% in 2025.

The analysis shows that a growing number of clinical trials, increasing R&D investment by pharmaceutical and biotech companies, and the expansion of hybrid and decentralized trials are driving market growth. The rapid development of biologics, biosimilars, and cell and gene therapies further boosts demand for specialized supply chain management. For instance, according to 2025 WHO statistics, approximately 162,704 clinical trials were conducted in China, indicating robust research activity.

Major Players Profiled in the Market Report:

• Thermo Fisher Scientific Inc. (U.S.)
• Parexel International (MA) Corporation (U.S.)
• Catalent Inc. (U.S.)
• Almac Group (U.K.)
• PCI Pharma Services (U.S.)
• Clinigen Limited (U.K.)
• Myonex (U.S.)
• Biocair (U.K.)
• Oximio (U.K.)
• KLIFO (Denmark)

Segments

Increasing Outsourcing to Propel Services Segment Growth

Based on type, the market is divided into products (investigational medicinal products, comparator drugs, ancillary supplies) and services (manufacturing, packaging, storage & distribution). The services segment holds the largest share, driven by increasing outsourcing of complex logistics, including planning, cold-chain distribution, and Direct-To-Patient (DTP) delivery.

High Volume of Trials to Drive Phase III Segment Expansion

By phase, the market is segmented into Phase I, II, III, and IV. The Phase III segment dominates with a 51.4% share in 2025, attributed to the large scale and complexity of these trials, which require extensive supplies and logistics management.

Manufacturing Advantages to Boost Small Molecules Segment